24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Teva Pharmaceutical Industries
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
09:39
Iran’s economy on ‘life support’ after one month of war
09:26
Five weeks in, Israel’s war costs near $15 billion
17:53
Team8 appoints Aaron Dubin and Daniel Goldstein as partners to lead new venture strategy initiative
17:27
The device that kept the downed F-15E navigator alive
More stories
Buzz
Most popular
Daily
Weekly
1
The Israeli safe room goes global as Gulf states face Iran's missile threats
2
The device that kept the downed F-15E navigator alive
3
Israel’s tallest tower planned: 111 floors in Ramat Gan “Vertical City”
4
Food delivery startup Haat raises $20 million at $100 million valuation to challenge Wolt in Tel Aviv
5
AI chip startup Hailo sees valuation halved to under $500 million ahead of urgent IPO
More news
Teva Pharmaceutical Industries
6 stories about Teva Pharmaceutical Industries
Troubled Drugmaker Teva to Axe over 4,000 Jobs
23.11.17
|
Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
New Teva CEO Kåre Schultz to Relocate to Israel
17.10.17
|
Golan Hazani
Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month
Teva’s Stock Drops After Approval of Copaxone Competitors
08.10.17
|
Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
The Ten Challenges Facing Teva's New CEO
12.09.17
|
Sophie Shulman
Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board
Teva Sells IUD Business for $1.1 Billion
12.09.17
|
Lilach Baumer
Going forward, the company will focus on central nervous system and respiratory treatments, shedding its Women's Health and Oncology and Pain businesses
Teva Appoints Lundbeck's Schultz as CEO
11.09.17
|
Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Previous Articles
